Advertisement

Enhanced Degradation of Serum Amyloid Protein SAA in vivo by Proteolytic Enzymes

  • J. B. Natvig
  • B. Skogen
  • E. Amundsen
Chapter

Abstract

Despite a considerable accumulation of new knowledge about amyloid proteins, the treatment of amyloidosis is very difficult and usually ineffective (1,2) for this reason many different approaches have been tried, including prevention of amyloid precursor synthesis, renovai or dissolution of amyloid fibrils and prevention of deposition of amyloid fibrils (Table 1). Discussions of these approaches have recently been published (3,4). We here report sane experiments in which proteolytic enzymes were used to enhance the degradation of amyloid precursor proteins, such as SAA. This can be achieved in vitro by the addition of proteolytic enzyme activators e.g. strepto-or urokinase to serum (5).

Keywords

Clearance Rate Amyloid Fibril Aspergillus Oryzae Amyloid Protein Plasma Cell Dyscrasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    G. G. Glenner, E. F. Osserman, E. P. Benditt, E. Caucins, A. S. Cohen and D. Zucker-Franklin, (Eds.) Amyloidosis, Plenum Press, New York, 857 pp. (1986)Google Scholar
  2. 2.
    J. Marrink and M. H. Van Rijswijk, (Eds.) Amyloidosis, Martinus Nijhoff Publ. Dordrecht, 378 pp. (1986)CrossRefGoogle Scholar
  3. 3.
    G. G. Glenner. Future Directions in Amyloid Research. In Amyloidosis, J. Marrink, M. H. Van Rijswijk (Eds.) Martinus Nijhoff, Dordrecht, pp. 357 (1986)Google Scholar
  4. 4.
    J. B. Natvig, B. Skogen and E. Amundsen, Therapeutic Prospects in Arayloidosis, m L. Minetti, G. D’Amico and C. Ponticelli (Eds.) The Kidney in Plasma Cell Dyscrasias, Martinus Nijhoff Publ. Dortrecht (In press)Google Scholar
  5. 5.
    B. Skogen and J. B. Natvig, In Vitro Enhancement of AA-degrading Activity in Human Plasma with the Plasminogen Activator Streptokinase. Scand J Immunol, 14:637 (1981)CrossRefGoogle Scholar
  6. 6.
    B. Skogen and E. Amundsen, Degradation of Amyloid Proteins with Protease I from Aspergillus Oryzae. In Vivo Increase in SAA Clearance Rate after Enzyme Infusion. Scand J Imnunol, 16:509 (1982)CrossRefGoogle Scholar
  7. 7.
    G. Lavie, D. Zucker-Franklin and E. C. Franklin, Degradation of Serum Amyloid A Protein by Surface-associated Enzymes of Human Blood Monocytes. J Exp Med 148:1020 (1978)CrossRefGoogle Scholar
  8. 8.
    B. Skogen, L. Thorsteinsson and J. B. Natvig, Degradation of Protein SAA to an AA-like Fragment by Enzymes of Monocytic Origin. Scand J Iirmunol, 11:533 (1980)CrossRefGoogle Scholar
  9. 9.
    B. Skogen, J. B. Natvig, A. L. Borresen and K. Berg, Degradation of Amyloid-related Serum Protein SAA by a Component Present in Rabbit and Human Serum. Scand J Immunol, 11:643 (1980)CrossRefGoogle Scholar
  10. 10.
    B. Skogen and J. B. Natvig, Degradation of Amyloid Proteins by Different Serine Proteases. Scand J Imnunol, 14:389 (1981)CrossRefGoogle Scholar
  11. 11.
    H. Eie, S. Kimura, W. D. Terry, J. Magnotta and G. G. Glenner, Amino Acid Sequence of an Amyloid Fibril Protein of unknown Origin. J. Biol. Chan. 247:5653 (1972)Google Scholar
  12. 12.
    D. E. Fitzgerald, E. P. Frisch and J. C. Milliken, Relief of Chronic Arterial Obstruction using Intravenous Brinase. Scand. J. Thor. Cardicvasc. Surg. 13:327 (1979)CrossRefGoogle Scholar
  13. 13.
    E. P. Frisch, S. Ekeström, D. E. Fitzgerald and F. Lund, Brinase Treatment in Patients Suffering from Advanced Peripheral Arterial Disease, pp 298 in J. F. Davidson, V. Cepelak, M. M. Samama and P. C. Desnoyers (Eds.) Progress in Chemical Fibrinolysis and Thromlbolysis. Vol. IV. Edinburgh, London and New York. Churchill Livingstone (1972)Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • J. B. Natvig
    • 1
  • B. Skogen
    • 2
  • E. Amundsen
    • 3
  1. 1.Institute of Immunology and RheumatologyNorway
  2. 2.The Regional Hospital m TransøTronsøNorway
  3. 3.Institute for Surgical Research RikshospitaletThe National HospitalOsloNorway

Personalised recommendations